Identification and Evaluation of Circulating Tumor Cells and Tumor Related Rare Cells in Immunotherapy

Identification and Evaluation of the Potential Biomarkers on Circulating Tumor Cells and Tumor Related Rare Cells in Cancer Patients Undergoing Immunotherapy

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03434912

Enrollment

Registered

2018-02-15

Start date

2017-05-24

Completion date

2020-04-30

Last updated

2018-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CTC and Tumor Related Rare Cell

Brief summary

The primary objective of this study is designed to evaluate the enumeration of circulating tumor cells and identify the potential biomarkers associated with clinical outcome. The secondary objective is to explore whether the changes of tumor related rare cells associates clinical outcome.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Evidence of a personally signed and dated informed consent document indicating that the subject (or a legal representative) has been informed of all pertinent aspects of the study. 2. Over 20 years of age. 3. Cancer patients on immune checkpoint inhibitors.

Exclusion criteria

1. Subjects who have other cancer history 2. Pregnant females 3. Subjects with active, known or suspected autoimmune disease. 4. Known history of human immunodeficiency virus (HIV)

Design outcomes

Primary

Measure	Time frame	Description
Circulating tumor cell	1 years	Isolation and analysis of circulating tumor cells before and after immunotherapy

Secondary

Measure	Time frame	Description
tumor related rare cell	1 years	Isolation and analysis of tumor related rare cells before and after immunotherapy

Countries

Taiwan

Contacts

Primary ContactWang Shin-Hang

henrywang@micareo.com886-2796-5096

Outcome results